| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/11/1999 | WO1999006393A1 Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them |
| 02/11/1999 | WO1999006391A1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof |
| 02/11/1999 | WO1999006390A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | WO1999006387A2 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |
| 02/11/1999 | WO1999006384A1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring |
| 02/11/1999 | WO1999006383A1 Piperazine derivatives active on the lower urinary tract |
| 02/11/1999 | WO1999006382A1 1,4-disubstituted piperazines |
| 02/11/1999 | WO1999006381A1 A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent |
| 02/11/1999 | WO1999006375A1 Fused heterocyclic compounds and their use as kynurenine-3-hydroxylase inhibitors |
| 02/11/1999 | WO1999006374A1 Condensed pyrazole compounds |
| 02/11/1999 | WO1999006372A1 Bis-acridinecarboxamides having antitumor activity |
| 02/11/1999 | WO1999006371A1 Heterocyclic derivatives which inhibit factor xa |
| 02/11/1999 | WO1999006368A1 Special 3-azabicyclo[3.1.0]hexanes, method for producing and modifying the same, and their use |
| 02/11/1999 | WO1999006367A1 Caspases and apoptosis |
| 02/11/1999 | WO1999006365A1 Mercaptoacylamino acids as metallo-beta-lactamase inhibitors |
| 02/11/1999 | WO1999006361A2 N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases |
| 02/11/1999 | WO1999006354A1 Il-8 receptor antagonists |
| 02/11/1999 | WO1999006351A1 Process for converting propargylic amine-n-oxides to enaminones |
| 02/11/1999 | WO1999006347A1 The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives |
| 02/11/1999 | WO1999006340A2 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
| 02/11/1999 | WO1999006114A2 Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases |
| 02/11/1999 | WO1999006057A1 Soya extract, process for its preparation and pharmaceutical composition |
| 02/11/1999 | WO1999006056A1 Use of physiologically acceptable vanadium compounds, salts and complexes |
| 02/11/1999 | WO1999006055A1 Polynucleotide compositions |
| 02/11/1999 | WO1999006053A1 N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 02/11/1999 | WO1999006052A1 Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| 02/11/1999 | WO1999006051A1 Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use |
| 02/11/1999 | WO1999006050A1 Remedial agent for baldness and other diseases |
| 02/11/1999 | WO1999006049A1 Integrin receptor antagonists |
| 02/11/1999 | WO1999006047A1 Use of rifamycin derivative for treating mastitis in a domestic animal |
| 02/11/1999 | WO1999006046A1 Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia |
| 02/11/1999 | WO1999006045A1 Controlled release pharmaceutical compositions containing tiagabine |
| 02/11/1999 | WO1999006044A1 Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
| 02/11/1999 | WO1999006043A1 Self-emulsifying formulation for lipophilic compounds |
| 02/11/1999 | WO1999006042A1 Caspases and apoptosis |
| 02/11/1999 | WO1999006041A1 SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
| 02/11/1999 | WO1999006040A1 Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof |
| 02/11/1999 | WO1999006039A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols |
| 02/11/1999 | WO1999006038A1 Fast-acting analgesic |
| 02/11/1999 | WO1999006036A1 Use of selective rxr agonists to prevent surgical adhesions |
| 02/11/1999 | WO1999006035A2 COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT |
| 02/11/1999 | WO1999006034A1 Coup-tfi directed therapies in the treatment of disease |
| 02/11/1999 | WO1999006033A2 An aqueous enteroclysis solution for the treatment of hepatic encephalopathy |
| 02/11/1999 | WO1999006032A2 Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production |
| 02/11/1999 | WO1999006029A1 Ascorbic acid-based formulation with improved colour stability |
| 02/11/1999 | WO1999006027A1 Pellet-type formulation intended for treating the intestinal tract |
| 02/11/1999 | WO1999006026A1 Stable particulate complexes with neutral or negative global charge of lamellar structure |
| 02/11/1999 | WO1999006025A1 Method and compositions for treating late phase allergic reactions and inflammatory diseases |
| 02/11/1999 | WO1999006024A1 Self-emulsifying formulation for lipophilic compounds |
| 02/11/1999 | WO1999006023A1 Ophthalmic compositions containing galactomannan polymers and borate |
| 02/11/1999 | WO1999006009A2 THERAPEUTIC PROCESS FOR INHIBITING NF-λB |
| 02/11/1999 | WO1999005920A1 Cooked cereal ingredient-containing products fortified with edta/iron compositions and methods for use |
| 02/11/1999 | WO1999005911A1 A method for modulation of circadian rhythmicity |
| 02/11/1999 | WO1998051290A3 Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent |
| 02/11/1999 | WO1998050397A3 Chimeric oligonucleotides and the use thereof |
| 02/11/1999 | WO1998033528A3 Induction of b cell tolerance |
| 02/11/1999 | WO1998030239A3 Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure |
| 02/11/1999 | DE19744353C1 Verfahren zur kontinuierlichen Herstellung von hydrolytisch abgebauter, ggfls. A process for the continuous production of hydrolytically degraded, if necessary. substituierter Stärke, Verwendung der hydrolytisch abgebauten Stärke und Vorrichtung zu ihrer Herstellung substituted starch, using the hydrolytically degraded starch and apparatus for the production thereof |
| 02/11/1999 | DE19734444A1 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung 3-substituted 3,4,5,7-tetrahydro-pyrrolo (3 ', 4': 4,5) thieno (2,3-d) pyrimidine derivatives, their preparation and use |
| 02/11/1999 | CA2299276A1 Tango-78, tango-79, and tango-81 nucleic acid molecules and polypeptides |
| 02/11/1999 | CA2299256A1 Tango-72 and tango-77 nucleic acid molecules and polypeptides |
| 02/11/1999 | CA2299055A1 Novel molecules of the tango-77 related protein family and uses thereof |
| 02/11/1999 | CA2299054A1 Compounds with anti-ks and anti-hiv activity |
| 02/11/1999 | CA2299045A1 Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them |
| 02/11/1999 | CA2298935A1 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them |
| 02/11/1999 | CA2298852A1 83 human secreted proteins |
| 02/11/1999 | CA2298851A1 Remedial agent for baldness and other diseases |
| 02/11/1999 | CA2298682A1 Mercaptoacylamino acids as metallo-beta-lactamase inhibitors |
| 02/11/1999 | CA2298668A1 Caspases and apoptosis |
| 02/11/1999 | CA2298624A1 Ascorbic acid-based formulation having improved colour stability |
| 02/11/1999 | CA2298617A1 Acyclic metalloprotease inhibitors |
| 02/11/1999 | CA2298595A1 Process for converting propargylic amine-n-oxides to enaminones |
| 02/11/1999 | CA2298544A1 Integrin receptor antagonists |
| 02/11/1999 | CA2298509A1 Special 3-azabicyclo[3.1.0]hexanes, method for producing and modifying the same, and their use |
| 02/11/1999 | CA2298115A1 Inhibitors of cell-cycle progression and uses related thereto |
| 02/11/1999 | CA2298061A1 Polynucleotide compositions |
| 02/11/1999 | CA2297988A1 Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors |
| 02/11/1999 | CA2297894A1 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
| 02/11/1999 | CA2297776A1 Base analogues |
| 02/11/1999 | CA2297757A1 Caspases and apoptosis |
| 02/11/1999 | CA2297755A1 Synthetic insulin mimetic substances |
| 02/11/1999 | CA2297489A1 Novel bone mineralization proteins, dna, vectors, expression systems |
| 02/11/1999 | CA2297407A1 Tricyclic vasopressin agonists |
| 02/11/1999 | CA2297096A1 Condensed heterocyclic compounds |
| 02/11/1999 | CA2297095A1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring |
| 02/11/1999 | CA2297076A1 Lyxofuranosyl benzimidazoles as antiviral agents |
| 02/11/1999 | CA2297012A1 Use of rifamycin derivative for treating mastitis in a domestic animal |
| 02/11/1999 | CA2296606A1 Fused heterocyclic compounds and their use as kynurenine-3-hydroxylase inhibitors |
| 02/11/1999 | CA2296485A1 N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 02/11/1999 | CA2296476A1 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |
| 02/11/1999 | CA2296394A1 Stable particulate complexes with neutral or negative global charge of lamellar structure |
| 02/11/1999 | CA2296315A1 Therapeutically active 1,2,4-triazolo(4.,3-b) pyridazine derivatives as ligands for gaba receptors |
| 02/11/1999 | CA2295945A1 Heterocyclic derivatives which inhibit factor xa |
| 02/11/1999 | CA2295807A1 Use of selective rxr agonists to prevent surgical adhesions |
| 02/11/1999 | CA2295295A1 Substituted alkanohydroxamic acids and method of reducing tnf.alpha. levels |
| 02/11/1999 | CA2294064A1 Il-8 receptor antagonists |
| 02/11/1999 | CA2294032A1 Self-emulsifying formulation for lipophilic compounds |
| 02/11/1999 | CA2291473A1 Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | CA2290746A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | CA2267559A1 Cooked cereal ingredient-containing products fortified with edta/iron compositions and methods for use |